Gold prices bounce off 3-week lows; demand likely longer term
Dennis Cho, Senior Vice President and Chief Legal Officer at Twist Bioscience Corp (NASDAQ:TWST), recently sold 806 shares of the company’s common stock. The biotechnology company, currently valued at $3.2 billion, has seen its stock surge 43% over the past year. According to InvestingPro analysis, the stock appears overvalued at current levels, despite maintaining a strong liquidity position with a current ratio of 5.0. The shares were sold on February 3, 2025, at an average price of $49.352 each, resulting in a total transaction value of $39,777. InvestingPro subscribers can access 10 additional key insights about TWST, including detailed analysis of its financial health and growth prospects. Following this sale, Cho holds 112,221 shares of Twist Bioscience. The sale was executed to cover tax withholding obligations related to the vesting of Restricted Stock Units, as per the company’s equity incentive plans.
In other recent news, Twist Bioscience has been the subject of several analyst upgrades following its robust financial performance in fiscal year 2024 and the first quarter of fiscal year 2025. Scotiabank (TSX:BNS) analyst Sung Ji Nam raised the company’s price target to $62, maintaining a Sector Outperform rating, following the company’s financial results that surpassed consensus predictions. The company’s full-year fiscal 2025 guidance was also revised upward, with expectations for total revenue growth of 19-21% year-over-year.
In addition, Barclays (LON:BARC) analyst Luke Sergott increased the price target on Twist Bioscience shares to $58, reiterating an Overweight rating. Sergott’s optimism is fueled by the company’s growing momentum in its Express portfolio and Next-Generation Sequencing (NGS) tools. Meanwhile, Baird maintained an Outperform rating and a $48.00 price target, highlighting the consistent pricing premiums for the company’s Express Genes service.
These recent developments also saw TD Cowen reiterating its Buy rating on Twist Bioscience with a price target of $58.00, signaling confidence in the company’s revenue and gross margin outlook for fiscal year 2025 and beyond. Lastly, Twist Bioscience’s strong performance at the end of fiscal year 2024 prompted Scotiabank to raise its price target to $54 from the previous target of $50, maintaining a Sector Outperform rating.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.